Near-infrared fluorescent probe for fast track of cyclooxygenase-2 in Golgi apparatus in cancer cells

Abstract

Cyclooxygenase-2 (COX-2) has been used as an excellent traceable biomarker, and exists maximally in Golgi apparatus (Cancer cells). Celecoxib (CCB) is a selective inhibitor for COX-2, and has been used as one of non-steroidal anti-inflammatory drug. Herein we report the conjugation of nile blue (NB) with CCB via a six-carbon linkage to form a fluorescence probe NB-C6-CCB for the detection of COX-2. NB-C6-CCB displays strong fluorescence with the emission peak centered at near-infrared wavelength (700 nm) in tumor cells or tumor tissues with high expression of COX-2. Importantly, NB-C6-CCB can discriminate cancer cells (MCF-7) fluorescence intensity from normal ones (COS-7) in the co-culture medium under confocal microscope. Subcellular localization of the NB-C6-CCB preferentially points to the Golgi apparatus and increases the fluorescent intensity. The competitive analysis (with CCB) and Native-PAGE analysis confirmed that NB-C6-CCB shows selective binding affinity towards COX-2 enzyme. Competitive analysis with CCB (flow cytometry assay) revealed the fluorescence intensity fluctuation due to pretreatment of CCB with different concentrations, indicating that the NB-C6-CCB is a precise or sensitive probe for the COX-2. Tumor tissue (depth: 500 µm), organs and mice imaging tests show excellent near-infrared visualization, specific localization and identification of tumors.

Graphical abstract

Keywords

cyclooxygenase-2 / nile blue / CCB / Golgi apparatus / NIR imaging

References

[1] Fass L. Imaging and cancer. Molecular Oncology, 2008, 2(2): 115–152

[2] Nguyen Q T, Olson E S, Aguilera T A, Jiang T, Scadeng M, Ellies L G, Tsien R Y. Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107(9): 4317–4322

[3] De Vries E F, Doorduin J, Dierckx R A, van Waarde A. Evaluation of [(11)C]rofecoxib as PET tracer for cyclooxygenase 2 overexpression in rat models of inflammation. Nuclear Medicine and Biology, 2008, 35(1): 35–42

[4] Wang Z, Gao H, Zhang Y, Liu G, Niu G, Chen X. Functional ferritin nanoparticles for biomedical applications. Frontiers of Chemical Science and Engineering, 2017, 11(4): 633–646

[5] Yukawa H, Baba Y. In vivo fluorescence imaging and the diagnosis of stem cells using quantum dots for regenerative medicine. ACS Analytical Chemistry, 2017, 89(5): 2671–2681

[6] Belloch J P, Rovira V, Llacer J L, Riesgo P A, Cremades A. Fluorescence-guided surgery in high grade gliomas using an exoscope system. Acta Neurochirurgica, 2014, 156(4): 653–660

[7] Stummer W, Reulen H J, Meinel T, Pichlmeier U, Schumacher W, Tonn J C, Rohde V, Oppel F, Turowski B, Woiciechowsky C, Franz K, Pietsch T. Extent of resection and survival on glioblastoma multiforme-identification of and adiustment for bias. Neurosurgery, 2008, 62(3): 564–574

[8] Wang B, Fan J, Wang X, Zhu H, Wang J, Mu H, Peng X. A nile blue based infrared fluorescent probe: Imaging tumors that over-express cyclooxygenase-2. RSC Chemical Communication, 2015, 51(4): 792–795

[9] Lin C W, Shulok J R, Kirley S D, Cincotta L, Foley J W. Lysosomal localization and mechanism of uptake of nile blue photosensitizers in tumor cells. Cancer Research, 1991, 51: 2710–2719

[10] Mao Z, Feng W, Li Z, Zeng L, Lv W, Liu Z. NIR in, far-red out: Developing a two-photon fluorescent probe for tracking nitric oxide in deep tissue. RSC Chemical Science, 2016, 7(8): 5230–5235

[11] Mao Z, Jiang H, Song X, Hu W, Liu Z. Development of a silicon-rhodamine based near-infrared emissive two-photon fluorescent probe for nitric oxide. ACS Analytical Chemistry, 2017, 89(18): 9620–9624

[12] Luchsinger C, Aguilar M, Burgos P V, Ehrenfeld P, Mardones G A. Functional disruption of the Golgi apparatus protein ARF1 sensitizes MDA-MB-231 breast cancer cells to the antitumor drugs actinomycin D and vinblastine through ERK and AKT signaling. PLoS One, 2018, 13(4): 1–25

[13] Wlodkowic D, Skommer J, McGuinness D, Hillier C, Darzynkiewicz Z. ER-Golgi network—a future target for anti-cancer therapy. Leukemia Research, 2009, 33(11): 1440–1447

[14] Sakhrani N M, Padh H. Organelle targeting: Third level of drug targeting. Drug Design, Development and Therapy, 2013, 7: 585–599

[15] Migita T, Inoue S. Implications of the Golgi apparatus in prostate cancer. International Journal of Biochemistry & Cell Biology, 2012, 44(11): 1872–1876

[16] Korkmaz C G, Korkmaz K S, Kurys P, Elbi C, Wang L, Klokk T I, Hammarstrom C, Troen G, Svindland A, Hager G L, Saatcioglu F. Molecular cloning and characterization of STAMP2, an androgen-regulated six transmembrane protein that is overexpressed in prostate cancer. Oncogene, 2005, 24(31): 4934–4945

[17] Uddin M J, Crews B C, Blobaum A L, Kingsley P J, Gorden D L, McIntyre J O, Matrisian L M, Subbaramaiah K, Dannenberg A J, Piston D W, Marnett L J. Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents. Cancer Research, 2010, 70(9): 3618–3627

[18] Uddin M J, Crews B C, Huda I, Ghebreselasie K, Daniel C K, Marnett L J. Trifluoromethyl fluorocoxib a detects cyclooxygenase-2 expression in inflammatory tissues and human tumor xenografts. ACS Medicinal Chemistry Letters, 2014, 5(4): 446–450

[19] Zhang H, Fan J, Wang J, Dou B, Zhou F, Cao J, Qu J, Cao Z, Zhao W, Peng X. Fluorescence discrimination of cancer from inflammation by molecular response to COX-2 enzymes. Journal of the American Chemical Society, 2013, 135(46): 17469–17475

[20] Keereweer S, Van Driel P B, Robinson D J, Lowik C W. Shifting focus in optical image-guided cancer therapy. Molecular Imaging & Biology, 2014, 16(1): 1–9

[21] Tian J, Yan Q, Zhu Y, Zhang J, Li J, Shi B, Xu G, Fan C, Zhao C. Enzyme-triggered fluorescence turn-on: A probe for specifically imaging ovarian-cancer-related g-glutamyltranspeptidase. Chinese Journal of Chemistry, 2017, 35(11): 1711–1716

[22] Sedgwick A C, Hayden A, Hill B, Bull S D, Elmes R B P, James T D. A simple umbelliferone based fluorescent probe for the detection of nitroreductase. Frontiers of Chemical Science and Engineering, 2018, 12(2): 311–331

[23] Gu K, Xu Y, Li H, Guo Z, Zhu S, Zhu S, Shi P, James T D, Tian H, Zhu W H. Real-time tracking and in vivo visualization of β-galactosidase activity in colorectal tumor with a ratiometric near-infrared fluorescent probe. Journal of the American Chemical Society, 2016, 138(16): 5334–5340

[24] Minchew C L, Didenko V V. Fluorescent probes detecting the phagocytic phase of apoptosis: Enzyme-substrate complexes of topoisomerase and DNA. Molecules (Basel, Switzerland), 2011, 16(6): 4599–4614

[25] Zhang H, Fan J, Wang J, Zhang S, Dou B, Peng X. An off-on COX-2-specific fluorescent probe: Targeting the Golgi apparatus of cancer cells. Journal of the American Chemical Society, 2013, 135(31): 11663–11669

[26] Gurram B, Zhang S, Li M, Li H, Xie Y, Cui H, Du J, Fan J, Wang J, Peng X. CCB conjugated fluorescent probe for identification and discrimination of cyclooxygenase-2 enzyme in cancer cells. ACS Analytical Chemistry, 2018, 90(8): 5187–5193

[27] Fan J, Guo S, Wang S, Kang Y, Yao Q, Wang J, Gao X, Wang H, Du J, Peng X. Lighting-up breast cancer cells by a near-infrared fluorescent probe based on KIAA1363 enzyme-targeting. RSC Chemical Communication, 2017, 53(35): 4857–4860

[28] Guo S, Fan J, Wang B, Xiao M, Li Y, Du J, Peng X. Highly selective red-emitting fluorescent probe for imaging cancer cells in situ by targeting pim-1 kinase. ACS Applied Materials & Interfaces, 2018, 10(2): 1499–1507

[29] Soslow R A, Dannenberg A J, Rush D, Woerner B M, Khan K N, Masferrer J, Koki A T. COX-2 is expressed in human pulmonary, colonic and mammary tumors. Cancer, 2000, 89(12): 2637–2645

[30] Richardsen E, Uglehus R D, Due J, Busch C, Busund L T. COX-2 is overexpressed in primary prostate cancer with metastatic potential and may predict survival. A comparison study between COX-2, TGF-beta, IL-10 and Ki67. Cancer Epidemiology, 2010, 34(3): 316–322

[31] Mrena J, Wiksten J P, Kokkola A, Nordling S, Ristimaki A, Haglund C. COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer. Tumour Biology, 2010, 31(1): 1–7

[32] Rizzo M T. Cyclooxygenase-2 in oncogenesis. Clinica Chimica Acta, 2011, 412(9-10): 671–687

[33] Bhardwaj A, Kaur J, Sharma S K, Huang Z, Wuest F, Knaus E E. Hybrid fluorescent conjugates of COX-2 inhibitors: Search for a COX-2 isozyme imaging cancer biomarker. Bioorganic & Medicinal Chemistry Letters, 2013, 23(1): 163–168

[34] Bhardwaj A, Kaur J, Wuest F, Knaus E E. Fluorophore-labeled cyclooxygenase-2 inhibitors for the imaging of cyclooxygenase-2 overexpression in cancer: Synthesis and biological studies. ChemMedChem, 2014, 9(1): 109–116, 240

[35] Hood W F, Gierse J K, Isakson P C, Kiefer J R, Kurumbail R G, Seibert K, Monahan J B. Characterization of CCB and valdecoxib binding to cyclooxygenase. Molecular Pharmacology, 2003, 63(4): 870–877

[36] Davis T W, O’Neal J M, Pagel M D, Zweifel B S, Mehta P P, Heuvelman D M, Masferrer J L. Synergy between CCB and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature. Cancer Research, 2004, 64(1): 279–285

[37] Shao D, Kan M, Qiao P, Pan Y, Wang Z, Xiao X, Li J, Chen L. CCB induces apoptosis via a mitochondriadependent pathway in the H22 mouse hepatoma cell line. Molecular Medicine Reports, 2014, 10(4): 2093–2098

[38] Xie S Q, Zhang Y H, Li Q, Wang J H, Li J H, Zhao J, Wang C J. COX-2-independent induction of apoptosis by CCB and polyamine naphthalimide conjugate mediated by polyamine depression in colorectal cancer cell lines. International Journal of Colorectal Disease, 2012, 27(7): 861–868

[39] Hu M, Fan J, Li H, Song K, Wang S, Cheng G, Peng X. Fluorescent chemodosimeter for Cys/Hcy with a large absorption shift and imaging in living cells. Organic & Biomolecular Chemistry, 2011, 9(4): 980–983

[40] Li H D, Yao Q C, Fan J L, Jiang N, Wang J Y, Xia J, Peng X J. A fluorescent probe for H2S in vivo with fast response and high sensitivity. RSC Chemical Communication, 2015, 51(90): 16225–16228

[41] Zhu H, Fan J, Wang J, Mu H, Peng X. An “enhanced PET”-based fluorescent probe with ultrasensitivity for imaging basal and elesclomol-induced HClO in cancer cells. Journal of the American Chemical Society, 2014, 136(37): 12820–12823

[42] Ahlgren P, Jarneving B, Rousseau R. Requirements for a cocitation similarity measure, with special reference to Pearson’s correlation coefficient. Journal of the American Society for Information Science and Technology, 2003, 54(6): 550–560

[43] Li M, Tian R, Fan J, Du J, Long S, Peng X. A lysosome-targeted BODIPY as potential NIR photosensitizer for photodynamic therapy. Dyes and Pigments, 2017, 147: 99–105

Acknowledgment

This work was financially supported by the National Natural Science Foundation of China (Grant Nos. 21421005, U1608222 and 21576037).

Electronic Supplementary Material

Supplementary material is available in the online version of this article at https://doi.org/10.1007/s11705-019-1790-7 and is accessible for authorized users.

RIGHTS & PERMISSIONS

2019 Higher Education Press and Springer-Verlag GmbH Germany, part of Springer Nature